Ładuje się......
Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
Clostridium difficile infection (CDI) is a leading nosocomial disease estimated to cause nearly half a million cases in the United States annually. Recurrent CDI (rCDI) affects ~25% of patients after completion of standard of care therapy and is associated with substantial health care costs and a ne...
Zapisane w:
| Wydane w: | Infect Drug Resist |
|---|---|
| Główni autorzy: | , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Dove Medical Press
2018
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6301304/ https://ncbi.nlm.nih.gov/pubmed/30588042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S159957 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|